Pituitary · 2026
68Ga-Pentixafor PET/MRI for identifying corticotroph adenomas in Cushing disease: a pilot study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fano Rodrigo, Nosov Anton, Ucpinar Burcin Agridag, Krebs Simone, Lyashchenko Serge, Theodorou Angeliki, Lin Andrew L, Tabar Viviane, Schoder Heiko, Geer Eliza B
Аннотация
PURPOSE: To assess whether C-X-C motif chemokine receptor 4-targeted 68Ga-Pentixafor PET/MRI can localize corticotroph adenomas in patients with Cushing disease (CD), particularly when MRI is negative or inconclusive, and explore performance in newly diagnosed versus persistent/recurrent disease.
METHODS: In this single-center pilot study, 10 patients with newly diagnosed or persistent/recurrent CD, confirmed by inferior petrosal sinus sampling (IPSS) and/or surgical pathology, underwent 68Ga-Pentixafor PET/MRI. Clinical, biochemical, radiologic, surgical, and postoperative data were reviewed. 68Ga-Pentixafor PET/MRI were classified as positive or negative using visual and quantitative assessment, including maximum standardized uptake values (SUVmax) and target-to-background (SUVmean of the blood pool in the cavernous sinus) ratio (TBR).
RESULTS: Participants had a mean age of 46.7 years; 9 were female. Five had newly diagnosed and 5 had persistent/recurrent CD. Two scans showed focal pituitary 68Ga-Pentixafor uptake compared to background pituitary tissue. One was confirmed by an MRI-visible lesion, positive pathology, and postoperative remission. The second occurred with an inconclusive MRI, negative pathology, and persistent postoperative disease; however, IPSS centralized. Three patients with negative scans underwent surgery and achieved remission, indicating false-negative imaging. Among 5 patients with negative scans who did not undergo subsequent surgery, 4 had persistent/recurrent CD and 1 had newly diagnosed CD treated medically.
CONCLUSION: In this pilot cohort, 68Ga-Pentixafor PET/MRI showed limited and variable performance for corticotroph adenoma localization. Although it may provide complementary information in selected patients with MRI-visible or equivocal lesions, further study is needed before it can be incorporated into diagnostic algorithms or considered an alternative to IPSS.
METHODS: In this single-center pilot study, 10 patients with newly diagnosed or persistent/recurrent CD, confirmed by inferior petrosal sinus sampling (IPSS) and/or surgical pathology, underwent 68Ga-Pentixafor PET/MRI. Clinical, biochemical, radiologic, surgical, and postoperative data were reviewed. 68Ga-Pentixafor PET/MRI were classified as positive or negative using visual and quantitative assessment, including maximum standardized uptake values (SUVmax) and target-to-background (SUVmean of the blood pool in the cavernous sinus) ratio (TBR).
RESULTS: Participants had a mean age of 46.7 years; 9 were female. Five had newly diagnosed and 5 had persistent/recurrent CD. Two scans showed focal pituitary 68Ga-Pentixafor uptake compared to background pituitary tissue. One was confirmed by an MRI-visible lesion, positive pathology, and postoperative remission. The second occurred with an inconclusive MRI, negative pathology, and persistent postoperative disease; however, IPSS centralized. Three patients with negative scans underwent surgery and achieved remission, indicating false-negative imaging. Among 5 patients with negative scans who did not undergo subsequent surgery, 4 had persistent/recurrent CD and 1 had newly diagnosed CD treated medically.
CONCLUSION: In this pilot cohort, 68Ga-Pentixafor PET/MRI showed limited and variable performance for corticotroph adenoma localization. Although it may provide complementary information in selected patients with MRI-visible or equivocal lesions, further study is needed before it can be incorporated into diagnostic algorithms or considered an alternative to IPSS.